middle.news
Noxopharm Advances SOF-SKN™ to Clinical Trials Amid Growing Global Collaborations
5:16am on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Noxopharm Advances SOF-SKN™ to Clinical Trials Amid Growing Global Collaborations
5:16am on Monday 2nd of June, 2025 AEST
Key Points
SOF-SKN™ passes final preclinical safety tests ahead of Phase 1 HERACLES trial
Follow-on Material Transfer Agreement signed with international partner to broaden Sofra™ platform research
Deepened collaboration with Hudson Institute of Medical Research to expand inflammation sensor studies
Issued A$2.6 million convertible notes to secure ongoing funding
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Noxopharm (ASX:NOX)
OPEN ARTICLE